SAN DIEGO, May 2, 2016 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it
will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, May 9, 2016, to discuss first quarter
2016 financial results and provide a corporate update. Arena will
issue a press release with its financial results after the NASDAQ
Global Select Market closes that day.
The conference call may be accessed by dialing 877.643.7155 for
domestic callers and 914.495.8552 for international callers. Please
specify to the operator that you would like to join the "Arena
Pharmaceuticals' First Quarter 2016 Financial Results and Corporate
Update Conference Call." The conference call will be webcast live
under the investor relations section of Arena's website at
www.arenapharm.com, and will be archived there for 30 days
following the call. Please connect to Arena's website several
minutes prior to the start of the broadcast to ensure adequate time
for any software download that may be necessary.
About Arena Pharmaceuticals
Arena embraces the challenge of improving health by seeking to
bring innovative medicines targeting G protein-coupled receptors to
patients. Arena's focus is discovering, developing and
commercializing drugs to address unmet medical needs, and
BELVIQ® (lorcaserin HCl) is Arena's first internally
discovered drug approved for marketing. Arena has US operations
located in San Diego, California,
and operations outside of the United
States, including its commercial manufacturing facility,
located in Zofingen, Switzerland.
For more information, visit Arena's website at
www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are
registered service marks of Arena Pharmaceuticals, Inc.
BELVIQ® is a registered trademark of Arena
Pharmaceuticals GmbH.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about the upcoming
conference call and related activities; embracing the challenge of
improving health; seeking to bring innovative medicines to
patients; and Arena's focus, plans, goals, strategy, expectations,
research and development programs, and ability to discover and
develop compounds and commercialize drugs. For such statements,
Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results
to differ materially from the forward-looking statements include,
but are not limited to, the following: recruiting and retaining key
management; the manner in which we focus and allocate our available
resources; having adequate funds and other assets and their
effective use; risks related to commercializing drugs, including
regulatory, manufacturing, supply and marketing issues, their
availability and use, and the focus, efforts and decisions of
collaborators; the entry into, modification or termination of
collaborative arrangements, and risks related to relying on such
arrangements; the timing and receipt of payments from others; the
risk that Arena's revenues are based in part on estimates, judgment
and accounting policies, and incorrect estimates or disagreement
regarding estimates or accounting policies may result in changes to
Arena's guidance or previously reported results; the timing and
outcome of regulatory review is uncertain, and lorcaserin may not
receive any additional marketing approvals; regulatory decisions in
one territory may impact other regulatory decisions and Arena's
business prospects; reimbursement and pricing decisions; the
timing, success and cost of Arena's research and development;
results of clinical trials and other studies are subject to
different interpretations and may not be predictive of future
results; clinical trials and other studies may not proceed at the
time or in the manner expected or at all; unexpected or unfavorable
new data; nonclinical and clinical data is voluminous and detailed,
and regulatory agencies may interpret or weigh the importance of
data differently and reach different conclusions than Arena or
others, request additional information, have additional
recommendations or change their guidance or requirements before or
after approval; data and other information related to any of
Arena's research and development may not meet regulatory
requirements or otherwise be sufficient for (or Arena or a
collaborator may not pursue) further research and development,
regulatory review or approval or continued marketing; Arena's and
third parties' intellectual property rights; and satisfactory
resolution of litigation or other disagreements. Additional factors
that could cause actual results to differ materially from those
stated or implied by Arena's forward-looking statements are
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Contact: Arena Pharmaceuticals, Inc.
Craig M. Audet, Ph.D., Senior
Vice President,
Operations & Head of Global Regulatory Affairs
caudet@arenapharm.com
858.453.7200, ext. 1612
www.arenapharm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-host-first-quarter-2016-financial-results-and-corporate-update-conference-call-and-webcast-on-monday-may-9-300260411.html
SOURCE Arena Pharmaceuticals, Inc.